IASLC WCLC 2026
Julia Rotow, MD, on Metastatic HER2-Mutant NSCLC: First-Line T-DXd
Julia Rotow, MD, of Dana-Farber Cancer Institute, discusses the primary results from the phase III DESTINY-Lung04 trial, which evaluated first-line trastuzumab deruxtecan (T-DXd), a HER2-directed anti...
Martin Reck, MD, PhD, on Resectable/Borderline Resectable NSCLC: Neoadjuvant Durvalumab Plus Chemotherapy
Martin Reck, MD, PhD, of LungenClinic Grosshansdorf, reviews efficacy and safety data from the primary analysis of MDT-BRIDGE. The phase II study is investigating perioperative durvalumab plus neoadju...
Alexander I. Spira MD, PhD, FACP, FASCO, on Metastatic EGFR-Mutated NSCLC: Global Study of Izalontamab Brenitecan
Alexander I. Spira MD, PhD, FACP, FASCO, of Virginia Cancer Specialists and US Oncology, discusses findings from a global phase I study of izalontamab brenitecan (BL-B01D1), an antibody-drug conjugate...
Chul Kim, MD, on NSCLC With EGFR Exon 20 Insertions: First-Line Amivantamab/Chemotherapy vs Chemotherapy
Chul Kim, MD, of Georgetown Cancer Institute, reviews findings from the phase III PAPILLON study, which found that first-line amivantamab plus carboplatin/pemetrexed was associated with numerically lo...
Chad G. Rusthoven, MD, on SCLC: Brain MRI Surveillance With or Without Prophylactic Cranial Irradiation
Chad G. Rusthoven, MD, of the University of Colorado School of Medicine, presents results from the international phase III SWOG S1827 MAVERICK trial, which showed that brain MRI surveillance alone imp...
Roy S. Herbst, MD, PhD, on Resected EGFR-Mutated NSCLC: Long-Term Overall Survival With Osimertinib
Roy S. Herbst, MD, PhD, of Dartmouth Cancer Center, discusses 8-year overall survival data from the landmark ADAURA trial, which showed the sustained long-term benefit of adjuvant therapy with osimert...
Alexander Drilon, MD, on Advanced Metastatic ROS1-Positive NSCLC: Zidesamtinib in TKI-Naive Patients
Alexander Drilon, MD, of Memorial Sloan Kettering Cancer Center, presents efficacy and safety data from a phase II cohort of the ARROS-1 trial, which included patients with locally advanced or metasta...
